Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 40, 2017, Pages 10743-10748

  Mazor, Tali ^a   Chesnelong, Charles ^b,c   Pankov, Aleksandr ^a   Jalbert, Llewellyn E ^d   Hong, Chibo ^a   Hayes, Josie ^a   Smirnov, Ivan V ^a   Marshall, Roxanne ^a   Souza, Camila F ^e,f   Shen, Yaoqing ^g   Viswanath, Pavithra ^d   Noushmehr, Houtan ^e,f   Ronen, Sabrina M ^d   Jones, Steven J M ^g,h   Marra, Marco A ^g,h   Cairncross, J Gregory ^c   Perry, Arie ^a   Nelson, Sarah J ^d   Chang, Susan M ^a   Bollen, Andrew W ^a   Molinaro, Annette M ^a   Bengtsson, Henrik ^a,i   Olshen, Adam B ^a,i   Weiss, Samuel ^b,c   Phillips, Joanna J ^a   Luchman, H Artee ^b,c   Costello, Joseph F ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HENRY FORD HEALTH SYSTEM   (United States)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g BRITISH COLUMBIA CANCER AGENCY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

2HG; Copy number; DNA methylation; Glioma; IDH1

Indexed keywords

2 HYDROXYGLUTARIC ACID; MESSENGER RNA; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CLONAL VARIATION; CONTROLLED STUDY; COPY NUMBER VARIATION; CPG ISLAND; DELETION MUTANT; DNA METHYLATION; EPIGENETICS; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GLIOMA; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IDH1 GENE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LONGITUDINAL STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR RECURRENCE; BRAIN TUMOR; GENE DELETION; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL CULTURE;

BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA METHYLATION; EPIGENOMICS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GLIOMA; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; MUTATION; NEOPLASM RECURRENCE, LOCAL; SEQUENCE DELETION; TUMOR CELLS, CULTURED;

EID: 85030264489     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1708914114     Document Type: Article

References (49)

1. Suzuki H, et al. (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468.
2. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153.
3. Johnson BE, et al. (2014) Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science 343:189–193.
4. Dang L, Yen K, Attar EC (2016) IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol 27:599–608.
5. Dang L, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744.
6. Losman JA, Kaelin WG, Jr (2013) What a difference a hydroxyl makes: Mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev 27:836–852.
7. Figueroa ME, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18:553–567.
8. Noushmehr H, et al.; Cancer Genome Atlas Research Network (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522.
9. Flavahan WA, et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529:110–114.
10. Eckel-Passow JE, et al. (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508.
11. Brat DJ, et al.; Cancer Genome Atlas Research Network (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498.
12. Lu C, et al. (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483:474–478.
13. Sasaki M, et al. (2012) IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 488:656–659.
14. Losman JA, et al. (2013) (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339:1621–1625.
15. Rohle D, et al. (2013) An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630.
16. Wang F, et al. (2013) Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–626.
17. + depletion. Cancer Cell 28:773–784.
18. Piaskowski S, et al. (2011) Glioma cells showing IDH1 mutation cannot be propagated in standard cell culture conditions. Br J Cancer 104:968–970.
19. Wakimoto H, et al. (2014) Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clin Cancer Res 20:2898–2909.
20. Yan H, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773.
21. Pusch S, et al. (2011) Glioma IDH1 mutation patterns off the beaten track. Neuropathol Appl Neurobiol 37:428–430.
22. Jin G, et al. (2013) Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 73:496–501.
23. Luchman HA, Chesnelong C, Cairncross JG, Weiss S (2013) Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line. Neuro Oncol 15:979–980.
24. Favero F, et al. (2015) Glioblastoma adaptation traced through decline of an IDH1 clonal driver and macro-evolution of a double-minute chromosome. Ann Oncol 26:880–887.
25. Chesnelong C, et al. (2014) Lactate dehydrogenase A silencing in IDH mutant gliomas. Neuro Oncol 16:686–695.
26. Mazor T, et al. (2015) DNA methylation and somatic mutations converge on the cell cycle and define similar evolutionary histories in brain tumors. Cancer Cell 28:307–317.
27. van Thuijl HF, et al. (2015) Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol 129:597–607.
28. Cavenee WK, et al. (1983) Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305:779–784.
29. Jin G, et al. (2011) 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 6:e16812.
30. Pietrak B, et al. (2011) A tale of two subunits: How the neomorphic R132H IDH1 mutation enhances production of αHG. Biochemistry 50:4804–4812.
31. Bralten LB, et al. (2011) IDH1 R132H decreases proliferation of glioma cell lines in vitro and in vivo. Ann Neurol 69:455–463.
32. Ward PS, et al. (2013) The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 288:3804–3815.
33. Elkhaled A, et al. (2012) Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 4:116ra5.
34. Jalbert LE, et al. (2017) Metabolic profiling of IDH mutation and malignant progression in infiltrating glioma. Sci Rep 7:44792.
35. Pusch S, et al. (2014) D-2-hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Acta Neuropathol Commun 2:19.
36. Kelly JJ, et al. (2010) Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro Oncol 12:745–755.
37. Luchman HA, et al. (2012) An in vivo patient-derived model of endogenous IDH1-mutant glioma. Neuro Oncol 14:184–191.
38. Kelly JJP, et al. (2009) Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells 27:1722–1733.
39. Brennan CW, et al.; TCGA Research Network (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477.
40. Ceccarelli M, et al.; TCGA Research Network (2016) Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164:550–563.
41. Hartmann C, Kluwe L, Lücke M, Westphal M (1999) The rate of homozygous CDKN2A/ p16 deletions in glioma cell lines and in primary tumors. Int J Oncol 15:975–982.
42. Ishii N, et al. (1999) Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 9:469–479.
43. SongTao Q, et al. (2012) IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269–273.
44. Johannessen TA, et al. (2016) Rapid conversion of mutant IDH1 from driver to passenger in a model of human gliomagenesis. Mol Cancer Res 14:976–983.
45. Okoye-Okafor UC, et al. (2015) New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol 11:878–886.
46. Medeiros BC, et al. (2017) Isocitrate dehydrogenase mutations in myeloid malignancies. Leukemia 31:272–281.
47. Nowak D, Stewart D, Koeffler HP (2009) Differentiation therapy of leukemia: 3 decades of development. Blood 113:3655–3665.
48. Inoue S, et al. (2016) Mutant IDH1 down-regulates ATM and alters DNA repair and sensitivity to DNA damage independent of TET2. Cancer Cell 30:337–348.
49. Sulkowski PL, et al. (2017) 2-hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med 9:eaal2463.